For personal use only BENITEC APPOINTS VICE-‐PRESIDENT MANUFACTURING Sydney Australia, 16 December 2014: ddRNAi therapeutics company Benitec Biopharma Limited (ASX: BLT, OTC: BTEBY)) is pleased to announce the appointment of Dr Claudia Kloth as its Vice President of Manufacturing. Dr Kloth has more than 14 years of experience in process development and cGMP manufacturing, most recently with gene therapy vectors, including adeno-‐associated viruses (AAV), which are being used by Benitec in the company’s hepatitis C (HCV), hepatitis B (HBV) and age-‐related macular degeneration (AMD) programs. Dr Kloth previously led Lonza’s process development group in the successful development, optimization, and transfer of robust, viral-‐based (adenovirus, AAV, lentivirus) and cell therapy products to cGMP manufacturing, through newly established scalable processes. Dr Kloth is based in the United States and will commence her role with Benitec on 5 January 2015. Dr Peter French, Chief Executive Officer and Managing Director at Benitec Biopharma welcomed the appointment of Dr Kloth. “This is a significant milestone in Benitec’s on-‐ going clinical development. Claudia brings a wealth of experience to Benitec to guide our development and scale-‐up of the AAV manufacturing requirements for our ddRNAi-‐ based therapeutics. We have taken this step now as we are confident that our TT-‐034 program is progressing well and we are looking at the next stage – scale-‐up of AAV manufacturing to service the potentially very large markets for our novel therapeutic products for HCV and HBV.” Dr Kloth said, “I am looking forward very much to joining Benitec. Benitec’s product pipeline is impressive, as are the vectors it is using or planning to use, and I am excited to be able to use my experience developing and manufacturing similar vectors to help Benitec progress its products through the clinic and onto the market with its transformational gene silencing technology.” For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com Company Investor relations Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: email@example.com Annabel Murphy Buchan Consulting Tel: +61 (2) 9237 8000 Email: AMurphy@buchanwe.com.au For personal use only About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-‐listed biotechnology company (ASX: BLT; OTC: BTEBY) which has developed a patented gene-‐silencing technology called ddRNAi or ‘expressed RNAi’. Based in Sydney, Australia with labs in Hayward CA (USA) and collaborators and licensees around the world, the company is developing ddRNAi-‐based therapeutics for chronic and life-‐threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet Age-‐related Macular Degeneration. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, intractable pain, Huntington’s disease and retinitis pigmentosa. For more information visit www.benitec.com.
© Copyright 2017 ExploreDoc